EMA Authorised: CellCept (mycophenolate mofetil) — Roche Registration GmbH

View source ↗

Summary

EMA has authorised CellCept (mycophenolate mofetil) under Roche Registration GmbH for use in graft rejection indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Roche Registration GmbH. Decision date: 26/03/2026